D-Pro2-endomorphin-1 and D-Pro2-endomorphin-2, respectively, attenuate the antinociception induced by endomorphin-1 and endomorphin-2 given intrathecally in the mouse

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 2, 2002, Pages 874-879

  Hung, Kuei Chun ^a   Wu, Hsiang En ^b   Mizoguchi, Hirokazu ^c   Sakurada, Shinobu ^d   Okayama, Toru ^d   Fujimura, Tsutomu ^e   Murayama, Kimie ^a   Sakurada, Tsukasa ^c   Fujimoto, James M ^a   Tseng, Leon F ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c FUJI CHEMICAL INDUSTRIES LTD   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEXTRO PROLINE ENDOMORPHIN 1; 2 DEXTRO PROLINE ENDOMORPHIN 2; ENDOMORPHIN 1; ENDOMORPHIN 2; MU OPIATE RECEPTOR; PROLINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, SPINAL; MALE; MICE; OLIGOPEPTIDES; PAIN MEASUREMENT; REACTION TIME;

EID: 0036828161     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.038927     Document Type: Article

References (24)

1. Chu XP, Xu NS, Li P, and Wang JQ (1999) Endomorphin-1 and endomorphin-2, endogenous ligands for the μ-opioid receptor, inhibit electrical activity of rat rostral ventrolateral medulla neurons in vitro. Neuroscience 93:681-686.
2. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
3. Goldberg IE, Rossi GC, Letchworth SR, Mathis JP, Ryan-Moro J, Leventhal L, Su W, Emmel D, Bolan EA, and Pasternak GW (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007-1013.
4. Hackler L, Zadina JE, GE LJ, and Kastin AJ (1997) Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptide 18:1635-1639.
5. Hylden JLK and Wilcox GL (1980) Intrathecal morphine in mice: A new technique. Eur J Pharmacol 167:313-316.
6. Krzanowska EK, Znamensky V, Wilk S, and Bodnar RJ (2000) Antinociceptive and behavioral activation responses elicited by D-Pro-endomorphin-2 in the ventrolateral periaqueductal gray are sensitive to sex and gonadectomy differences in rats. Peptides 21:705-715.
7. Martin-Schild S, Gerall AA, Kastin AJ, and Zadina JE (1998) Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides 19:1783-1789.
8. Martin-Schild S, Gerall AA, Kastin AJ, and Zadina JE (1999) Differential distribution of endomorphin-1- and endomorphin-2-like immunoreactivities in the CNS of the rodent. J Comp Neurol 405:450-471.
9. Martin-Schild S, Zadina JE, Gerall AA, Vigh S, and Kastin AJ (1997) Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides 18:1641-1649.
10. Mizoguchi H, Narita M, Oji DE, Suganuma C, Nagase H, Sora I, Uhl GR, Cheng EY, and Tseng LF (1999) μ-Opioid receptor gene-dose dependent reductions in G-protein activation in the pons/medulla and antinociception induced by endomorphins in μ-opioid receptor knockout mice. Neuroscience 94:203-207.
11. 35S]GTPγS binding in the mouse spinal cord. Eur J Pharmacol 351:383-387.
12. Ohsawa M, Mizoguchi H, Narita M, M. Chu, Nagase H, and Tseng LF (2000) Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 294:1106-1111.
13. Ohsawa M, Mizoguchi H, Narita M, Nagase H, Kampine JP, and Tseng LF (2001) Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 298:592-597.
14. Pierce TL, Grahek MD, and Wessendorf MW (1998) Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport 9:385-389.
15. Sakurada S, Hayashi T, Yuhki M, Fujimura T, Kastin AJ, Murayama K, Yonezawa A, Sakurada C, Takeshita M, Zadina JE, et al. (2000) Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone. Brain Res 881:1-8.
16. Sakurada S, Zadina JE, Kastin AJ, Katsuyama S, Fujimura T, Murayama K, Yuki M, Ueda H, and Sakurada T (1999) Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. Eur J Pharmacol 372:25-30.
17. Shane R, Wilk S, and Bodnar RJ (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815:278-286.
18. Shreff M, Schulz S, Wiborny D, and Hollt V (1998) Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport 9:1031-1034.
19. Stone LS, Fairbanks CA, Laughlin TM, Nguyen HO, Bushy TM, Wessendorf MW, and Wilcox GL (1997) Spinal analgesia actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8:3131-3135.
20. Tseng LF, Narita M, Suganuma C, Mizoguchi H, Ohsawa M, Nagase H, and Kampine JP (2000) Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292:576-583.
21. Williams CA, Wu SY, Dun SL, Kwok EH, and Dun NJ (1999) Release of endomorphin-2 like substances from the rat spinal cord. Neurosci Lett 273:25-28.
22. Wu SY, Dun SL, Wright MT, Chang JK, and Dun NJ (1999) Endomorphin-like immunoreactivity in the rat dorsal horn and inhibition of substantia gelatinosa neurons in vitro. Neuroscience 89:317-321.
23. Wu HE, Hung KC, Mizoguchi H, Fujimoto JM, and Tseng LF (2001) Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse. J Pharmacol Exp Ther 299:1120-1125.
24. Zadina JE, Hacker L, and Kastin AJ (1997) A potent and selective endogenous agonist for the μ-opiate receptor. Nature (Lond) 386:499-502.